Clinical trial

Study of REGN3500 and Dupilumab in Patients With Asthma

NCT03112577

Study summary

ClinicalTrials.gov

Study of REGN3500 and Dupilumab in Patients With Asthma

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention REGN3500 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Dupilumab Normalized identity: dupilumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fluticasone propionate Normalized identity: fluticasone propionate View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-06-15

PhasePHASE1

Conditions

Asthma, Allergicunresolved

Interventions

REGN3500DRUG

DupilumabDRUG · verified · RxNorm: dupilumab

PlaceboDRUG

Fluticasone propionateDRUG · verified · RxNorm: fluticasone propionate

Sponsors & collaborators

Regeneron Pharmaceuticalslead sponsor

Sanoficollaborator

Mapped research locations

LondonUnited Kingdom2 ManchesterUnited Kingdom1 BelfastUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03112577 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.